Keyword: Shire

Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.

The IPO will tee Translate up to trial an mRNA candidate designed to enable all cystic fibrosis patients to produce fully functional CTFR proteins.

Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.

The IPO would give Avrobio the means to trial gene therapies designed to supplant enzyme replacement therapies from Sanofi, Shire and Pfizer.

Takeda's $62 billion acquisition of Shire added $31 billion to its debt load. Now, it's looking to cut costs where it can.

Takeda's plan involves signing on one or more large, long-term investors, as well as keeping its R&D pipeline alive by discarding programs that don't deliver.

Kamada has hit another hurdle in its bid to bring the first inhaled treatment for AAT deficiency to market as an alternative to intravenous drugs.

Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.

Caladrius is boosting its pipeline with a late-stage cell therapy for refractory angina.

The companies are part of a star-studded commission that is working on a road map for improving outcomes in rare diseases.